What Is VIP Studied For? Research Areas, Per the Literature

Answer first

Vasoactive intestinal peptide, usually shortened to VIP, is a naturally occurring signalling peptide that has been investigated mainly in laboratory settings: cultured cells, isolated tissue and animal models. The published research areas that recur most often concern inflammation and the lung, exocrine gland secretion, autoimmunity, reproductive tissue biology, and neural circuits in the retina and cortex. An editorial reviewing the historic perspective and future potential of VIP described it as a peptide of long standing scientific interest across endocrine, metabolic and immune research (PMID 23094826).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms or treatment. A broader background overview sits on the VIP learn page.

Research area 1: lung inflammation and fibrosis

One of the more recent contexts in which VIP signalling appears is neuroimmune control of lung injury. A 2025 study in Immunity examined nociceptor sensory neurons and reported that these neurons suppressed alveolar macrophage-induced, Siglec-F positive neutrophil-mediated inflammation and thereby protected against pulmonary fibrosis in a mouse model (PMID 40449484). The work sits in the broader field of neuropeptide signalling between sensory nerves and immune cells. The model was murine lung injury, not human lung disease, and the study did not test an approved therapy in patients (PMID 40449484).

What that does and does not establish

Animal lung fibrosis models are widely used because fibrosis is difficult to study prospectively in humans, but findings in mice do not transfer automatically to human disease. The 2025 report described cellular mechanisms rather than clinical outcomes (PMID 40449484).

Research area 2: exocrine secretion and salivary glands

VIP has a long association with secretion from glands. A 2020 study in Pflugers Archiv examined salivary mucous cells and reported that VIP and muscarinic stimulation produced synergistic mucin secretion, with the effect mediated by enhanced protein kinase C activity following VIP-induced release of an intracellular calcium pool (PMID 31932898). That was cell and tissue level work on secretory mechanism, not a clinical investigation of dry mouth or any named condition (PMID 31932898). Researchers in that line of work were characterising second messenger pathways, which is a mechanistic question rather than a treatment question.

Research area 3: autoimmunity and diabetes models

VIP has been studied for immunoregulatory properties in autoimmune disease models. A 2006 paper in the Annals of the New York Academy of Sciences investigated plasmid DNA-mediated VIP gene transfer in non-obese diabetic (NOD) mice, a standard model of autoimmune type 1 diabetes, and described a protective role for that gene transfer approach in the model (PMID 16888188). The intervention tested was gene transfer in mice rather than administration of a peptide product to people, and the study population was an inbred mouse strain selected for spontaneous autoimmunity (PMID 16888188).

The 2012 editorial on VIP framed immune and metabolic signalling as a recurring theme across decades of VIP research and discussed future potential rather than established clinical use (PMID 23094826).

Research area 4: reproductive tissue and implantation biology

A 2018 paper in Molecular and Cellular Endocrinology reported that VIP induced the decidualization program and conditioned immunoregulation of the implantation process (PMID 28689770). Decidualization is the transformation of endometrial stromal cells that prepares the uterine lining for embryo implantation, and the study addressed that cellular program together with the local immune environment (PMID 28689770). This is laboratory reproductive biology. The paper did not report fertility outcomes in patients (PMID 28689770).

Research area 5: retinal neurons

VIP is expressed by a defined class of retinal interneurons. A 2024 review in Eye covered retinal VIP-amacrine cells and summarised their development, structure and function (PMID 38066110). Amacrine cells shape signalling between bipolar cells and retinal ganglion cells, so this literature treats VIP primarily as a neuronal marker and neuromodulator inside visual circuitry (PMID 38066110). A review of this kind synthesises prior work and does not itself test an intervention.

Research area 6: cortical circuits and VIP-expressing interneurons

In neuroscience, VIP labels a major subtype of inhibitory interneuron. A 2023 study in Communications Biology examined the role of interneuron subtypes, including VIP-expressing interneurons, in controlling trial-by-trial output variability in the neocortex (PMID 37620550). The question there was circuit level: how different inhibitory cell classes contribute to the reliability of cortical responses (PMID 37620550). That research area concerns endogenous VIP-expressing cells in the brain rather than any administered compound.

Summary table of research areas

Where the evidence is weak, preclinical only, or absent

Several things commonly associated with the phrase "VIP uses" are not supported by the papers verified for this page, and that should be stated plainly rather than softened.

• Chronic inflammatory illness in humans. The lung work cited here was conducted in a mouse model (PMID 40449484). No human clinical trial of VIP appears in the verified citation set for this page.
• Type 1 diabetes in people. The protective finding described was gene transfer in NOD mice (PMID 16888188), which is a model system and not a patient population.
• Fertility outcomes. The implantation research addressed a cellular program and local immune conditioning (PMID 28689770), not pregnancy rates.
• Vision or cognition outcomes. The retinal and cortical papers described endogenous VIP-expressing neurons (PMID 38066110, PMID 37620550), not outcomes after administering anything.
• Dosing information. No dose, schedule or route is stated anywhere on this page, because the verified papers above do not provide clinical dosing that could be summarised responsibly.

Adverse Events: What Studies Report

The verified papers summarised here are mechanistic and preclinical in nature, and none of them was designed as a safety or tolerability trial of VIP in humans. The mouse lung study reported immune cell behaviour and fibrosis outcomes in the model rather than drug safety endpoints (PMID 40449484), and the salivary cell study reported secretory and signalling measurements in cells (PMID 31932898). The 2006 NOD mouse work described a gene transfer strategy and its effect in that model (PMID 16888188). Because no human adverse event dataset appears in this citation set, no adverse event profile for VIP can be stated from these sources. Absence of reported adverse events in mechanistic papers is not evidence of safety; it reflects what those studies were built to measure.

Reading this evidence carefully

Three distinctions help when interpreting VIP literature. First, the difference between endogenous biology and administered compound: much VIP research describes what the peptide or VIP-expressing cells do naturally in tissue, as in the retinal and cortical work (PMID 38066110, PMID 37620550). Second, the difference between a model and a patient population, as in the NOD mouse study (PMID 16888188). Third, the difference between mechanism and outcome: showing that VIP triggers a signalling pathway in cells (PMID 31932898) is a different claim from showing that anything improves in a person. An editorial can set out future potential (PMID 23094826) without that potential having been demonstrated clinically.

Regulatory status

VIP is not approved by the FDA as a medicine for any condition. This page is not guidance. Materials labelled for research use only are not medicines and are not intended for human administration. Nothing above should be read as a recommendation, and any health decision belongs with a licensed physician who knows the individual case.

References

• Nociceptor neurons suppress alveolar macrophage-induced Siglec-F(+) neutrophil-mediated inflammation to protect against pulmonary fibrosis (Immunity, 2025)
• VIP and muscarinic synergistic mucin secretion by salivary mucous cells is mediated by enhanced PKC activity via VIP-induced release of an intracellular Ca(2+) pool (Pflugers Archiv, 2020)
• Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice (Annals of the New York Academy of Sciences, 2006)
• VIP induces the decidualization program and conditions the immunoregulation of the implantation process (Molecular and Cellular Endocrinology, 2018)
• Retinal VIP-amacrine cells: their development, structure, and function (Eye, 2024)
• Role of interneuron subtypes in controlling trial-by-trial output variability in the neocortex (Communications Biology, 2023)
• Editorial: vasoactive intestinal peptide (VIP): historic perspective and future potential (Endocrine, Metabolic and Immune Disorders Drug Targets, 2012)